Next Article in Journal
Natural Language Processing Applications for Computer-Aided Diagnosis in Oncology
Next Article in Special Issue
A Familial Case of Multiple Endocrine Neoplasia 2A: From Morphology to Genetic Alterations Penetration in Three Generations of a Family
Previous Article in Journal
Head-to-Head Comparison of Nasopharyngeal, Oropharyngeal and Nasal Swabs for SARS-CoV-2 Molecular Testing
Previous Article in Special Issue
Reinducing Radioiodine-Sensitivity in Radioiodine-Refractory Thyroid Cancer Using Lenvatinib (RESET): Study Protocol for a Single-Center, Open Label Phase II Trial
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
Diagnostics
Volume 13
Issue 2
10.3390/diagnostics13020285
diagnostics-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles thumb_up
...
Endorse textsms
...
Comment
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Article

Thyroid Collision Tumors: The Presence of the Medullary Thyroid Carcinoma Component Negatively Influences the Prognosis

by
Ion Negura
1,2,†,
Victor Ianole
1,2,†,
Mihai Danciu
1,2,*,
Cristina Preda
2,3,
Diana Gabriela Iosep
4,
Radu Dănilă
4,5,
Alexandru Grigorovici
4,5 and
Delia Gabriela Ciobanu Apostol
1,2
1
Pathology Department, Grigore T. Popa University of Medicine and Pharmacy Iasi, 700115 Iasi, Romania
2
Sf. Spiridon Emergency Clinical Hospital Iasi, 700111 Iasi, Romania
3
Endocrinology Department, Grigore T. Popa University of Medicine and Pharmacy Iasi, 700115 Iasi, Romania
4
Faculty of Medicine, Grigore T. Popa University of Medicine and Pharmacy Iasi, 700115 Iasi, Romania
5
Surgical Department, Sf. Spiridon Emergency Clinical Hospital Iasi, 700111 Iasi, Romania
*
Author to whom correspondence should be addressed.
†
These authors contributed equally to this work.
Diagnostics 2023, 13(2), 285; https://doi.org/10.3390/diagnostics13020285
Submission received: 14 December 2022 / Revised: 30 December 2022 / Accepted: 9 January 2023 / Published: 12 January 2023
(This article belongs to the Special Issue Recent Advances in Thyroid Carcinoma)
Browse Figures
Review Reports Versions Notes

Abstract

:
Thyroid collision tumors (TCTs) are rare pathological findings, representing <1% of thyroid cancers. This study aimed to compare the main pathological features of TCTs containing medullary thyroid carcinoma (MTC) and papillary thyroid carcinoma (PTC) components with MTC-only tumors and PTC-only tumors. Methods: The retrospective study included 69 cases diagnosed with TCTs (with simultaneous MTC and PTC components), MTC and PTC. All tumors were comparatively assessed for the classical histopathological prognostic features, including a new grading system for MTC. Results: The main component of TCTs had more frequent microscopic extrathyroidal extension (mETE) (p = 0.000), lymphovascular invasion (LVI) (p = 0.000), perineural invasion (PNI) (p = 0.044), and lymph node metastasis (p = 0.042). Additionally, the TCTs’ MTC component presented with more frequent LVI (p = 0.010). Comparing TCTs’ MTC and PTC components with MTC-only tumors and PTC-only tumors revealed that only the TCTs’ MTC components had statistically significant more frequent mETE (p = 0.010) than MTC-only tumors. When applied to the MTC component of TCTs, the pathological parameters of the new grading system of MTC showed no correlations with other microscopic or clinical aspects. Conclusion: Using classical pathological prognostic features, the comparative analysis revealed that the main TCTs’ component was more aggressive than the minor one. Contrary to PTCs, in TCTs, the medullary component was more aggressive than the papillary one, but also more aggressive than MTC-only tumors.

1. Introduction

Thyroid collision tumors (TCTs) are rare entities, described as the simultaneous presence of more than one morphologically distinct tumor developing within the same organ, separated by non-neoplastic tissue, without a histological mixture of the different tumor cells [1,2,3]. Collision tumors can involve various regions and organs throughout the body, with cases reported in the kidney, ovary, lung, colon, and stomach [4,5,6,7,8], but they are a rare entity in the thyroid gland, representing less than 1% of all thyroid malignancies [1,9,10]. The most frequent association encountered in TCTs is the synchronous presence of medullary thyroid carcinoma (MTC) and papillary thyroid carcinoma (PTC) components [1,11]. Still, other combinations have been reported in the literature, including squamous cell carcinoma (SCC) and PTC, PTC and follicular thyroid carcinoma (FTC), Hurthle cell thyroid carcinoma (HTC) associated with PTC and poorly differentiated thyroid carcinoma (PDTC), and HTC associated with MTC [12,13,14,15].
Collision tumors with MTC and PTC components are encountered more frequently in female patients, with an F/M ratio of two to one, with the majority of cases presenting in the fifth to seventh decades of life [1,16]. Very often, after clinical and paraclinical investigations, only one component of these collision tumors is recognized, and the other component is an incidental histopathological finding [17]. It is important to mention each component in the histopathological report and to include all high-risk features: microscopic extrathyroidal extension (mETE), multifocality, perineural invasion (PNI), lymphovascular invasion (LVI), and lymph node metastasis (LNM) [18], because a complete report covering all these microscopic aspects for each component of the tumor is critical for therapy [19]. Recently, a grading system for MTC which includes mitotic activity/2 mm2, Ki67 proliferation index and tumor necrosis was proposed [20]. According to this grading system, MTC is considered high-grade if presents at least one of the following microscopic aspects: tumor necrosis, ≥5 mitoses/2 mm2 or Ki67 proliferation index ≥5% [20].
In the literature, as a consequence of the scarcity of these thyroid tumors, there is uncertainty regarding what is the essential feature of TCTs for therapy (the component with more aggressive behavior or the component having a higher stage at diagnosis) [1,11,12]. Therefore, we aimed to better understand the pathological differences between collision tumors and tumors of the thyroid with only one component. We retrospectively analyzed TCTs with MTC and PTC components and compared these components between them and with a similar number of PTC-only and MTC-only thyroid carcinomas with the same pathological T category (pT).

2. Materials and Methods

2.1. Study Group

The study group included 35 cases of TCTs, from which 23 cases with MTC and PTC components were subtracted in order to be compared with 23 cases of MTC-only tumors and 23 cases of PTCs. The inclusion criterion for PTC-only and MTC-only thyroid carcinomas was an equal pathological T category compared to the TCTs’ components. The database included the following information about the patients: age at diagnosis (younger than 55 years and older than 55 years), gender, location of the tumor (right thyroid lobe, left thyroid lobe, isthmus), and risk stratification factors, such as: pre-operative serum calcitonin levels (4 groups: 11–99 pg/mL, 100–499 pg/mL, 500–999 pg/mL, ≥1000 pg/mL), tumor size (<10 mm, 10–40 mm, and >40 mm), growth patterns, amyloid presence, focality of the tumor (≥2 foci), mitotic activity/2 mm2, Ki67 proliferation index (%) and tumor necrosis (present/absent) for TCTs’ MTC component and MTC-only tumors, mETE (presence of malignant cells in peri-thyroidal soft tissues including skeletal muscle, adipose tissue, vessels, and nerve bundles), LVI, PNI, LNM, coexisting thyroid pathology, pathologic T category (pT) and American Joint Committee of Cancer (AJCC) stage (8th edition, 2017) [21].
The research was performed following the ethical standards of the Helsinki declaration regarding the patients’ informed consent for the use of medical information for scientific purposes. The Ethics Committee of the “Sf. Spiridon” Clinical Emergency Hospital County Iasi approved the research project.

2.2. Pathological Evaluation

According to our internal protocol, the post-operatory thyroid specimen was fixed in 10% neutral buffered formalin and grossed by cutting transverse sections at 5 mm intervals. If a tumor was less than 3 cm, the tumor was entirely processed; if the tumor was larger than 3 cm, a minimum of 2 blocks per centimeter were mandatory. The capsule (if present) was completely sampled, regardless of tumor diameter. Tumor-free thyroid lobe and isthmus were sampled with one block/cm of thyroid tissue. All resected lymph nodes were submitted for microscopic evaluation.
In this retrospective study, the hematoxylin and eosin (HE), trichromic stains (Congo red, van Gieson) and immunohistochemistry (IHC) slides for all cases were independently re-evaluated by two senior pathologists according to the latest American Joint Committee of Cancer (8th edition, 2017) [21] and WHO Classification of Tumours of Endocrine Organs (4th Edition, 2017) [22], and restaged, where necessary. For immunophenotype confirmation, we used the following immunohistochemical markers: calcitonin, chromogranin, synaptophysin, CD56, thyroglobulin, HBME1, Galectin-3 and CK19.

2.3. Statistical Analysis

The statistical analysis was performed using Microsoft Office Excel and SPSS V.26-SPSS Inc., IBM Corporation, Chicago, IL, USA. The Chi-squared test and Fisher’s exact test were applied to assess the correlations between five elements considered to be essential for risk stratification (lymphovascular invasion, multifocality, microscopic extrathyroidal extension, perineural invasion, and lymph node metastasis), as well as patients’ clinicopathological aspects (age at diagnosis, gender, pre-operative serum calcitonin levels, mitotic activity/2 mm2, Ki67 proliferation index and tumor necrosis for TCTs’ MTC component and MTC-only tumors, tumor size, thyroid location, growth patterns, stromal amyloid, pathologic T category, AJCC stage, and coexisting thyroid pathology). For the comparative analysis, the independent t-test was used to compare the variables (elements considered essential for risk stratification and clinicopathological aspects of the patients) of the two components of the TCTs between them and with similar PTC-only and MTC-only thyroid tumors. Every test was 2-sided, and a p-value < 0.05 (5%) was considered statistically significant.

3. Results

3.1. Epidemiological and Pathological Characteristics of Collision Tumors Cohort

We retrospectively examined the epidemiological and pathological characteristics of 35 cases of TCT (10 males, 25 females, M/F = 0.40), with a mean age at diagnosis of 61.54 years (range 40–77 years), diagnosed in our hospital between 2008 and 2022 (Table 1).
When comparing the main component with the minor one (Table 2), we observed a statistically significant difference in the following pathological characteristics: diameter, microscopic extrathyroidal extension (mETE), LVI, PNI, LNM, pathologic T category and AJCC stage, pointing out that the main component was more aggressive.

3.2. Pathological Characteristics of TCTs with MTC and PTC Components and Comparison with MTC-Only Tumors and PTCs

Out of 35 TCT cases diagnosed over a 15 year period, 23 cases (65.71%) were diagnosed as collision tumors with MTC and PTC components (7 males, 16 females, M/F = 0.43; mean age of 61.6 years, range 42–77 years) (Table 1).

3.2.1. Comparison between MTC and PTC Components of TCTs

When comparing the MTC and PTC components (Figure 1) (Table 3), the following pathological characteristics, diameter, LVI, pathologic T category and AJCC stage, had statistically significant differences, pointing out that the MTC component was more aggressive.

3.2.2. Analysis of Prognostic Factors of MTC Component of TCTs

To evaluate the correlations between pathological features with prognostic value, we assessed the associations between age at diagnosis, gender, pre-operative serum calcitonin levels, tumor size, location, growth pattern, stromal amyloid, mitotic activity/2 mm2, Ki67 proliferation index, tumor necrosis pathologic T category, AJCC stage, coexisting thyroid pathology, and five elements considered to be essential for risk stratification, namely, PNI, LVI, mETE, multifocality, and LNM (Table S1).
Statistically significant correlations were observed between LVI (present vs. absent) and the pre-operative serum calcitonin levels (p = 0.005), with a strong correlation for calcitonin levels ≥1000 pg/mL. Additionally, LVI had statistically significant correlations with pathologic T category (p = 0.001), AJCC stage (p = 0.000), tumor size (p = 0.002), and presence of amyloid (p = 0.036).
Lymph node metastases due to TCTs’ MTC component (present vs. absent) had statistically significant correlations with the pre-operative serum calcitonin levels (p = 0.005), with a strong correlation at calcitonin levels ≥1000 pg/mL. Additionally, LNM had statistically significant correlations with pathologic T category (p = 0.005), AJCC stage (p = 0.000), and tumor size (p = 0.006).
Microscopic extrathyroidal extension due to TCTs’ MTC component (present vs. absent) had statistically significant correlations with the pathologic T category (p = 0.025) and AJCC stage (p = 0.044).
Focality of the TCTs’ MTC component (unifocal vs. multifocal) had statistically significant correlations with the gender of the patients (p = 0.020).

3.2.3. Analysis of Prognostic Factors of MTC-Only Tumors

LVI (present vs. absent) had statistically significant correlations with tumor size (p = 0.032) and with AJCC stage (p = 0.023). Statistically significant correlations between the focality of the tumors (unifocal vs. multifocal) and growth patterns were present (p = 0.024) (Table 4).

3.2.4. TCTs’ MTC Component vs. MTC-Only Tumors

The main clinical and pathological features of TCT’s MTC component are presented in Table 1. The growth patterns of the TCTs’ MTC component were variable: they were solid in 15 cases (65.21%) (Figure 2A), insular in 4 cases (17.39%), trabecular in 3 cases (13.04%), and lobular in 1 case (4.34%). By contrast, MTC-only tumors had only three growth patterns: they were solid in 19 cases (82.60%), and insular and trabecular in 2 cases (8.69%) each. Amyloid was identified in 13 cases (56.52%) (Figure 2B) of TCTs with MTC components, compared to 12 (52.17%) cases of MTC-only tumors.
TCTs’ MTC component and MTC-only tumors were multifocal in three cases (13.04%), each. Microscopic ETE due to TCTs’ MTC component was present in eight cases (34.78%), with LVI in eleven cases (47.82%) (Figure 2C), and PNI in three cases (13.04%), while MTC-only cases presented with mETE and PNI in one case (4.34%) each, and with LVI in eight cases (34.78%).
Based on mitotic activity/2 mm2, Ki67 proliferation index and tumor necrosis, only one (4.34%) TCT’s MTC component was high-grade compared to four cases (17.39%) of MTC-only tumors.
Lymph node metastasis due to TCTs’ MTC component was present in seven cases (30.43%) (Figure 2D). In comparison, there were six cases (26.08%) with lymph node metastasis due to MTC-only tumors. IHC tests were performed to demonstrate the MTC component, including calcitonin (Figure 2E), chromogranin (Figure 2F), and synaptophysin, when necessary.
When comparing the TCTs’ MTC component with MTC-only tumors, (Table 5), only mETE due to TCTs’ MTC components had a statistically significant difference, pointing out that MTC component was more aggressive.

3.2.5. Analysis of Prognostic Factors of PTC Component of TCTs

Statistically significant correlations (Table S2) were observed between LVI due to TCTs’ PTC component and pathologic T category (p = 0.034). Additionally, LVI had statistically significant correlations with tumor size (p = 0.034). mETE, due to TCTs’ PTC component, had statistically significant correlations with tumor size (p = 0.034) and pathologic T category (p = 0.034). TCTs’ PTC component focality had statistically significant correlations with the growth patterns (p = 0.014).

3.2.6. Analysis of Prognostic Factors of PTC-Only Tumors

Only LVI had statistically significant correlations (Table S3) with age at diagnosis (p = 0.021), tumor size (p = 0.002), growth patterns (p = 0.048) and pathologic T category (p = 0.011).

3.2.7. TCTs’ PTC Component vs. PTC-Only tumors

The main clinical and pathological features of TCT’s PTC component are presented in Table 1.
TCTs’ PTC component and PTC-only tumors had only two major growth patterns, with 12 cases (52.17%) of a follicular growth pattern (Figure 3A) and 11 cases (47.82%) of a conventional growth pattern (Figure 3B) for TCTs’ PTC component. PTC-only tumors had conventional growth patterns in 14 cases (60.86%) and follicular growth patterns in 9 cases (39.13%).
IHC tests to demonstrate the PTC component, including CK19 (Figure 3C), Galectin-3 (Figure 3D), HBME1 (Figure 3E), and CD56 (Figure 3F), were performed when necessary. No statistically significant differences (Table S4) between TCTs’ PTC component and PTC-only tumors were observed.

4. Discussion

TCT represents a particular category of thyroid tumors with different pathogenesis compared to mixed or composite thyroid tumors [1,23]. These terms were used interchangeably in the thyroid gland to designate multiple concomitant tumors composed of parafollicular C cells and follicular cellular elements [24]. However, these terms are not similar and indicate distinct neoplastic entities [25]. Collision tumors are synchronous, morphologically distinct tumors, developing within the same organ and separated by non-neoplastic tissue, without a histological mixture of the different tumor cells [1,13]. Mixed tumors, which, according to WHO 2017 [22] are synonymous to composite tumors, are malignant thyroid tumors with histopathological and immunohistochemical aspects of follicular and parafollicular C cells that coexist intermixed in the same thyroid tumor [26]. The source of mixed/composite tumors is a common driver mutation that induces divergent cellular differentiation, which gives rise to two or more different intermingled cellular populations [27].
In mixed medullary-follicular thyroid carcinoma (MMFTC), because of a common cell of origin, tumor cells are positive (individual cells or separate cell clusters) for both thyroglobulin and calcitonin within the same lesion [28], while TCTs composed of MTC and follicular components are positive for calcitonin only in the MTC component and thyroglobulin only in the follicular component, as a consequence of different pathogeneses (origin from two or more different cell progenitors separated by non-neoplastic tissue) [16]. Multiple hypotheses tempted to explain the development of TCTs. The first is the “chance theory”, which suggests a separate origin for components of TCTs and the synchronous development of the components by chance [13]. A second hypothesis assumes that the initial tumor can modify the microenvironment to promote the occurrence and development of another tumor [3]. Another theory suspects the development of two or more separate driver mutations in the same stem cell that induce the occurrence of two or more independent tumors [13]. Nonetheless, there is still uncertainty regarding the pathogenesis of TCTs, as many case reports of TCT with molecular analysis performed to identify the cell of origin for these tumors communicate different and conflicting results [1,11,16,29,30].
Different studies published results indicate that some pathological features, namely the focality of the tumor, extrathyroidal extension, lymphovascular invasion, perineural invasion, and lymph node metastasis, can be crucial prognostic factors in thyroid carcinomas [31,32,33,34,35]. In addition to these high-risk pathological features, in the case of MTC, ≥5 mitoses/2 mm2, Ki67 proliferation index ≥ 5% or tumor necrosis are considered poor prognostic factors, and when at least one is microscopically identified, the tumor is considered high-grade [20]. To our knowledge, this is the first study which analyzes the MTC component of TCTs using the recently proposed International Medullary Thyroid Carcinoma Grading System [20]. Additionally, considering the rarity of this entity (1% of the entire thyroid neoplastic pathology) [10], we consider that the selected TCT cases are relevant. With 23 cases of TCT with MTC and PTC components, our series is the third-largest one described in literature, after those published by Appetecchia et al. in 2019 (183 patients) [1] and Biscolla et al. in 2004 (27 patients) [29].
The present study mainly aimed to analyze high-risk histopathological features (mETE, multifocality, LVI, and LNM) of each TCT’s MTC and PTC components and to compare them with those of similar MTC-only and PTC-only thyroid tumors in order to document the differences between these separate entities. We also compared the high-risk histopathological features of each component to point out which one is more aggressive. Eventually, a univariate analysis was performed to document the correlations (for each TCT component with MTC-only and PTC-only tumors) between the high-risk histopathological features and the patients’ main pathological features.
When comparing the high-risk histopathological features of TCTs’ components with similar thyroid carcinomas, only TCTs’ MTC component had a statistically significant more aggressive behavior than MTC-only tumors. In opposition to our study, Biscolla et al. found no different behavior of TCTs’ MTC component compared to MTC-only tumors when analyzing the epidemiologic, clinical, and pathologic features, stating that the association of PTC component in a TCT does not influence the outcome of the MTC [29].
Regarding the behavior of the components present in the 23 cases of TCT with MTC and PTC components, when comparing the high-risk histopathological features of the two components between them, the MTC components were more aggressive, presenting with more frequent LVI. Additional statistically significant differences, implying a more aggressive behavior of the MTC components, were present, when comparing the diameter and AJCC stage, pointing out that the TCTs’ main components were more aggressive in our study.
MTC was invariably the main component in our case series (20/23 cases) (86.95%). The results regarding the behavior of the two components (MTC and PTC) reported in our study are similar with the results of Appetecchia et al. and Thomas et al. [1,11]. Both our study and Thomas et al.’s study found a more aggressive behavior of the MTC component than the PTC one, observations sustained by the larger mean tumor size, higher frequency of ETE, LVI, more frequent LNM due to the MTC component, and a higher stage compared to PTC component [11].
The female preponderance (18F/9M, F/M = 2) that we found in our study was similar to the results of Biscolla et al. (16F/7M F/M = 2.28) [29] and Appetecchia et al. (105F/78M F/M = 1.34) [1], while the case series published by Thomas et al. had a slight male preponderance (10F/11M F/M = 0.90) [11]. In contrast to our study, where the mean age of the patients was 61.7 years (range 42–77 years), the studies published by Appetecchia et al., Biscolla et al. and Thomas et al. communicate a lower mean age of 56.2 (range 16–84 years) [1], 49.9 (range 27–76 years) [29], and 45.3 years (range 26–77 years) [11], respectively. On the other hand, the study published by Biscolla et al. had only six cases (22.22%) with both components involving the same thyroid lobe [29], while in our study there were twelve cases (52.17%), similar to Thomas et al. (11/21–52.38%) [11]. Micro-PTC was present in 20/23 cases (86.95%) of TCT with MTC and PTC components in our study, a percentage which is close to those reported by Appetecchia et al., with 148/183 (81%) [1], Biscolla et al., with 21/27 cases (77.77%) [29], and Thomas et al., with 18/21 cases (85.71%) [11]. In most of our patients, both components were located in the same thyroid lobe (52.17%), similar to Thomas et al. (52.38%) [11]. This supports the theory suggesting that the initial tumor can modify the microenvironment to promote the occurrence and development of another tumor. In contrast, the study performed by Biscolla et al. had 21 of 27 cases (77%) with MTC and the PTC located in different thyroid lobes [29], suggesting that these two carcinomas are two different diseases with no interconnection.
The disparate results reported by our study when compared to those published by Biscolla et al. and Thomas et al. may be explained by different grossing protocols, particularly of the uninvolved thyroid lobe by a tumor. Another reason might be the existence of hard-to-recognize MTC variants (oncocytic, follicular, and pseudopapillary subtypes), which may be incorrectly diagnosed as HTC, FTC, or PTC [36].
There was no statistically significant difference, in our study, between TCTs’ MTC components and MTC-only cases when the high-risk pathological features (≥5 mitoses/2 mm2, Ki67 proliferation index ≥ 5% or tumor necrosis) were compared. Contrary to the study published by Xu et al. [20], we observed no correlations between these high-risk pathological features and PNI, LVI, mETE, multifocality, and LNM.
Our study had some limitations. For instance, we could not correlate the pathological data with the cytological examination for all our patients. Yet, the management of these cases was not negatively influenced. Additionally, no molecular tests were performed.
Because TCT is rare, treatment protocols are poorly defined; some authors assume that the two components of TCT should be treated as two distinct concomitant primaries [3], while others argue that the treatment should focus on the component with the most aggressive features [1,12]. The treatment protocol of TCTs is complex and needs to consider the stage of the tumor but also clinical and morpho-pathological signs of aggressiveness for each component; thus, these tumors are best managed by an interdisciplinary team that can elaborate an individualized therapy scheme for these patients [37]. In the case of TCTs with MTC and PTC components, total thyroidectomy is the recommended surgical procedure because of the aggressive behavior of the MTC component, which can be multicentric and involve both lobes at the same time [38]. Additionally, the increased incidence of tumor LVI in TCTs with an MTC component requires neck dissection with lymphadenectomy in the central and lateral compartment for staging and locoregional tumor control [1,29,39]. T category of the main component and pre-operative serum calcitonin levels are the significant factors guiding prophylactic neck lymph node dissection in clinical and paraclinical node-negative cases [40]. Adjuvant radioactive iodine therapy is required if the TCTs PTC component is grouped in a high or intermediate-risk category in the risk stratification scheme [41,42]. In the study published by Biscolla et al., the outcome of the patients with TCT having an MTC component was not affected by the PTC component or radioiodine treatments [29]. One possible explanation might be that the TCTs PTC component was an incidental m-PTC without high-risk features in most of his cases. In our study, three cases of the PTC component with a maximum diameter over 20 mm but not more than 40 mm (T2 category) showed variable proportions of high-risk features, such as multifocality, microscopic ETE, LVI, and lymph node metastasis. These different therapeutic strategies that consider many clinical and morpho-pathological aspects impose the need for a complete microscopic evaluation for each TCTs component, including high-risk aspects, to manage this particular category of patients better.

5. Conclusions

MTC and PTC are the most common components of TCTs. The prognosis is influenced by the component with the higher stage and the most aggressive behavior, which most frequently is the MTC component, as in our study and in most cases reported in literature. Regarding the high-risk histopathological features, only mETE due to TCTs’ MTC component proved to be statistically different compared to MTC-only tumors, pointing out that TCTs’ MTC component may be more aggressive than MTC-only tumors. When applied to MTC component of TCTs, the pathological parameters of the recently proposed International Medullary Thyroid Carcinoma Grading System showed no correlations with other microscopic or clinical aspects.
Although our study is one of the largest published to date, further studies are necessary to analyze the differences and the outcome of patients with TCTs composed of MTC and PTC compared to MTC-only and PTC-only cases, to better understand the pathogenesis, behavior, and optimal management of these cases.

Supplementary Materials

The following are available online at https://www.mdpi.com/article/10.3390/diagnostics13020285/s1, Table S1: Pathological characteristics of TCTs’ MTC components in relation to the histopathological prognostic features. Table S2: Pathological characteristics of TCTs’ PTC components in relation to the histopathological prognostic features. Table S3: Pathological characteristics of PTC-only tumors in relation to the histopathological prognostic features. Table S4: Pathological characteristics of the TCTs’ PTC component compared to PTC-only tumors

Author Contributions

Conceptualization, I.N., V.I. and D.G.C.A.; Methodology, I.N., V.I. and D.G.C.A.; Validation, M.D. and D.G.C.A.; Formal analysis, I.N. and V.I.; Investigation, I.N., V.I., M.D., C.P., D.G.I., R.D., A.G. and D.G.C.A.; Data curation, I.N., V.I. and D.G.I.; Writing—original draft preparation, I.N., V.I. and D.G.C.A.; Writing—review & editing, M.D. and D.G.C.A. All authors have read and agreed to the published version of the manuscript.

Funding

This research was funded by Grigore T. Popa University of Medicine and Pharmacy, Iasi, Romania.

Institutional Review Board Statement

The study was conducted in accordance with the Declaration of Helsinki and approved by the Ethics Committee of “Sf. Spiridon” Emergency County Hospital, Iasi, Romania (2021).

Informed Consent Statement

Not applicable.

Data Availability Statement

Not applicable.

Conflicts of Interest

The authors declare no conflict of interest.

References

  1. Appetecchia, M.; Lauretta, R.; Barnabei, A.; Pieruzzi, L.; Terrenato, I.; Cavedon, E.; Mian, C.; Castagna, M.G.; Elisei, R.; on behalf of the SIE (Italian Society of Endocrinology) Working Group. Epidemiology of Simultaneous Medullary and Papillary Thyroid Carcinomas (MTC/PTC): An Italian Multicenter Study. Cancers 2019, 11, 1516. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  2. Jain, M.; Verma, D.; Thomas, S.; Chauhan, R. Mixed medullary–papillary carcinoma thyroid: An uncommon variant of thyroid carcinoma. J. Lab. Physicians 2014, 6, 133–135. [Google Scholar] [CrossRef]
  3. Bojoga, A.; Stănescu, L.; Badiu, C. Collision tumors of the thyroid. A special clinical and pathological entity. Arch. Clin. Cases 2021, 8, 84–90. [Google Scholar] [CrossRef] [PubMed]
  4. Lamprou, S.; Glykas, I.; Fragkoulis, C.; Theodoropoulou, G.; Koutsonikas, G.; Papadopoulos, G. Collision kidney tumor with clear cell renal cell carcinoma and papillary type 1 renal cell carcinoma. A case report and review of the literature. Urologia 2022, 89, 304–306. [Google Scholar] [CrossRef]
  5. Alayed, A.M.; Almawi, A.S.; Alghamdi, E.G.; Alfaleh, H.S.; Kadasah, N.S. Ovarian Collision Tumor, Massive Mucinous Cystadenoma, and Benign Mature Cystic Teratoma. Cureus 2021, 13, e16221. [Google Scholar] [CrossRef]
  6. Suzuki, S.; Ohtsuka, T.; Hato, T.; Kamiyama, I.; Goto, T.; Kohno, M.; Emoto, K.; Hayashi, Y. Primary pulmonary collision tumor with three components in the underlying interstitial lung disease. Thorac. Cancer 2014, 5, 460–462. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  7. Kataoka, J.; Nitta, T.; Ota, M.; Fujii, K.; Ishii, M.; Senpuku, S.; Ueda, Y.; Tsuchimoto, Y.; Takeshita, A.; Miyatake, J.; et al. Collision Tumor Comprising Primary Malignant Lymphoma and Adenocarcinoma in the Ascending Colon. Case Rep. Gastroenterol. 2021, 15, 379–388. [Google Scholar] [CrossRef] [PubMed]
  8. Kitagawa, H.; Kaneko, M.; Kano, M.; Ibuki, Y.; Amatya, V.J.; Takeshima, Y.; Hirabayashi, N.; Hirota, S. Coexistence of gastrointestinal stromal tumor and leiomyosarcoma of the stomach presenting as a collision tumor: A case report and review of literature. Pathol. Int. 2018, 68, 313–317. [Google Scholar] [CrossRef] [PubMed]
  9. Plauche, V.; Dewenter, T.; Walvekar, R.R. Follicular and papillary carcinoma: A thyroid collision tumor. Indian J. Otolaryngol. Head Neck Surg. 2013, 65, 182–184. [Google Scholar] [CrossRef] [Green Version]
  10. Brandwein-Gensler, M.; Urken, M.; Wang, B. Collision tumor of the thyroid: A case report of metastatic liposarcoma plus papillary thyroid carcinoma. Head Neck 2004, 26, 637–641. [Google Scholar] [CrossRef]
  11. Thomas, A.; Mittal, N.; Rane, S.U.; Bal, M.; Patil, A.; Ankathi, S.K.; Vaish, R. Papillary and Medullary Thyroid Carcinomas Presenting as Collision Tumors: A Case Series of 21 Cases at a Tertiary Care Cancer Center. Head Neck Pathol. 2021, 15, 1137–1146. [Google Scholar] [CrossRef] [PubMed]
  12. Ryan, N.; Walkden, G.; Lazic, D.; Tierney, P. Collision tumors of the thyroid: A case report and review of the literature. Head Neck 2015, 37, E125–E129. [Google Scholar] [CrossRef]
  13. Pishdad, R.; Cespedes, L.; Boutin, R.; Jaloudi, M.; Raghuwanshi, M. Coexistence of Two Different Thyroid Malignancies: A Collision Phenomenon. Cureus 2020, 12, e7539. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  14. Toyoshima, M.T.K.; Domingues, R.B.; Soares, I.C.; Danilovic, D.L.S.; Amorim, L.C.; Cavalcante, E.R.C.; Antonacio, F.F.; Roitberg, F.S.R.; Hoff, A.O. Thyroid collision tumor containing oncocytic carcinoma, classical and hobnail variants of papillary carcinoma and areas of poorly differentiated carcinoma. Arch. Endocrinol. Metab. 2021, 65, 495–499. [Google Scholar] [CrossRef]
  15. Yeap, Z.H.; Arman, S.; Stenhouse, G.; Isa, A. Synchronous Hürthle cell and medullary thyroid carcinomas. BMJ Case Rep. 2022, 15, e248879. [Google Scholar] [CrossRef]
  16. Rossi, S.; Fugazzola, L.; De Pasquale, L.; Braidotti, P.; Cirello, V.; Beck-Peccoz, P.; Bosari, S.; Bastagli, A. Medullary and papillary carcinoma of the thyroid gland occurring as a collision tumour: Report of three cases with molecular analysis and review of the literature. Endocr. Relat. Cancer 2005, 12, 281–289. [Google Scholar] [CrossRef]
  17. Furuya-Kanamori, L.; Bell, K.J.L.; Clark, J.; Glasziou, P.; Doi, S.A.R. Prevalence of Differentiated Thyroid Cancer in Autopsy Studies Over Six Decades: A Meta-Analysis. J. Clin. Oncol. 2016, 34, 3672–3679. [Google Scholar] [CrossRef]
  18. Bradley, N.L.; Wiseman, S.M. Papillary thyroid microcarcinoma: The significance of high risk features. BMC Cancer 2017, 17, 142. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  19. Durante, C.; Filetti, S. Management of papillary thyroid cancer patients in absence of postoperative radioiodine remnant ablation: Tailoring follow-up by neck sonography. J. Clin. Endocrinol. Metab. 2011, 96, 3059–3061. [Google Scholar] [CrossRef] [Green Version]
  20. Xu, B.; Fuchs, T.L.; Ahmadi, S.; Alghamdi, M.; Alzumaili, B.; Bani, M.A.; Baudin, E.; Chou, A.; De Leo, A.; Fagin, J.A.; et al. International Medullary Thyroid Carcinoma Grading System: A Validated Grading System for Medullary Thyroid Carcinoma. J. Clin. Oncol. 2022, 40, 96–104. [Google Scholar] [CrossRef]
  21. Amin, M.B.; Greene, F.L.; Edge, S.B.; Compton, C.C.; Gershenwald, J.E.; Brookland, R.K.; Meyer, L.; Gress, D.M.; Byrd, D.R.; Winchester, D.P. The Eighth Edition AJCC Cancer Staging Manual: Continuing to build a bridge from a population-based to a more “personalized” approach to cancer staging. CA Cancer J. Clin. 2017, 67, 93–99. [Google Scholar] [CrossRef] [PubMed]
  22. DeLellis, R.A.; Ghuzlan, A.; Saavedra, A.J.; Baloch, Z.W.; Baloso, F.; Elisei, R.; Kaserer, K.; LiVolsi, V.; Matias-Guiu, X.; Mete, O.; et al. Medullary thyroid carcinoma. In World Health Organization (WHO) Classification of Tumours of Endocrine Organs, 4th ed.; Lloyd, R.V., Osamura, R.Y., Kloppel, G., Rosai, J., Eds.; WHO International Agency for Research on Cancer (IARC) Press: Lyon, France, 2017; Volume 10, pp. 108–116. [Google Scholar]
  23. Gurkan, E.; Gurbuz, Y.; Tarkun, I.; Canturk, Z.; Cetinarslan, B. Mixed medullary-papillary carcinoma of the thyroid: Report of two cases and review of the literature. Indian J. Pathol. Microbiol. 2014, 57, 598–602. [Google Scholar] [CrossRef] [PubMed]
  24. Dionigi, G.; Castano, P.; Bertolini, V.; Boni, L.; Rovera, F.; Tanda, M.L.; Capella, C.; Bartalena, L.; Dionigi, R. Simultaneous medullary and papillary thyroid cancer: Two case reports. J. Med. Case Rep. 2007, 1, 133. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  25. Lax, S.F.; Beham, A.; Kronberger-Schönecker, D.; Langsteger, W.; Denk, H. Coexistence of papillary and medullary carcinoma of the thyroid gland-mixed or collision tumour? Clinicopathological analysis of three cases. Virchows Arch. 1994, 424, 441–447. [Google Scholar] [CrossRef]
  26. Chambers, M.; Tafe, L.J.; Gutmann, E.J.; Kerr, D.A. Cytologic features of a case of mixed medullary and follicular cell-derived thyroid carcinoma with review of the literature. Diagn. Cytopathol. 2021, 49, E125–E129. [Google Scholar] [CrossRef] [PubMed]
  27. Sung, C.T.; Shetty, A.; Menias, C.O.; Houshyar, R.; Chatterjee, S.; Lee, T.K.; Tung, P.; Helmy, M.; Lall, C. Collision and composite tumors; radiologic and pathologic correlation. Abdom. Radiol. 2017, 42, 2909–2926. [Google Scholar] [CrossRef] [Green Version]
  28. Ueki, I.; Ando, T.; Haraguchi, A.; Horie, I.; Imaizumi, M.; Hayashi, T.; Uga, T.; Usa, T.; Kawakami, A. A case of mixed medullary and follicular cell carcinoma of the thyroid. Intern. Med. 2011, 50, 1313–1316. [Google Scholar] [CrossRef] [Green Version]
  29. Biscolla, R.P.; Ugolini, C.; Sculli, M.; Bottici, V.; Castagna, M.G.; Romei, C.; Cosci, B.; Molinaro, E.; Faviana, P.; Basolo, F.; et al. Medullary and papillary tumors are frequently associated in the same thyroid gland without evidence of reciprocal influence in their biologic behavior. Thyroid 2004, 14, 946–952. [Google Scholar] [CrossRef]
  30. Papi, G.; Corrado, S.; Pomponi, M.G.; Carapezzi, C.; Cesinaro, A.; LiVolsi, V.A. Concurrent lymph node metastases of medullary and papillary thyroid carcinoma in a case with RET oncogene germline mutation. Endocr. Pathol. 2003, 14, 269–276. [Google Scholar] [CrossRef]
  31. Oliver, J.R.; Patel, K.N.; Chang, C.M.; Baldwin, C.K.; Brar, P.C.; Morris, L.G.T.; Givi, B. Lymph node metastases in pediatric medullary thyroid carcinoma. Surgery 2021, 170, 736–742. [Google Scholar] [CrossRef]
  32. Kim, M.; Kim, W.G.; Jeon, M.J.; Kim, H.K.; Yi, H.S.; Kim, E.S.; Kim, B.H.; Kim, W.B.; Shong, Y.K.; Kang, H.C.; et al. Modification of the Tumor-Node-Metastasis Staging System for Differentiated Thyroid Carcinoma by Considering Extra-Thyroidal Extension and Lateral Cervical Lymph Node Metastasis. Endocrinol. Metab. 2020, 35, 149–156. [Google Scholar] [CrossRef]
  33. Sezer, A.; Celik, M.; Yilmaz Bulbul, B.; Can, N.; Tastekin, E.; Ayturk, S.; Ustun, F.; Guldiken, S.; Sut, N. Relationship between lymphovascular invasion and clinicopathological features of papillary thyroid carcinoma. Bosn. J. Basic. Med. Sci. 2017, 17, 144–151. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  34. Clark, J.R.; Fridman, T.R.; Odell, M.J.; Brierley, J.; Walfish, P.G.; Freeman, J.L. Prognostic variables and calcitonin in medullary thyroid cancer. Laryngoscope 2005, 115, 1445–1450. [Google Scholar] [CrossRef]
  35. Torresan, F.; Cavedon, E.; Mian, C.; Iacobone, M. Long-Term Outcome After Surgery for Medullary Thyroid Carcinoma: A Single-Center Experience. World J. Surg. 2018, 42, 367–375. [Google Scholar] [CrossRef] [PubMed]
  36. Thomas, C.M.; Asa, S.L.; Ezzat, S.; Sawka, A.M.; Goldstein, D. Diagnosis and pathologic characteristics of medullary thyroid carcinoma—Review of current guidelines. Curr. Oncol. 2019, 26, 338–344. [Google Scholar] [CrossRef] [Green Version]
  37. Mitchell, A.L.; Gandhi, A.; Scott-Coombes, D.; Perros, P. Management of thyroid cancer: United Kingdom National Multidisciplinary Guidelines. J. Laryngol. Otol. 2016, 130, S150–S160. [Google Scholar] [CrossRef] [PubMed]
  38. Griebeler, M.L.; Gharib, H.; Thompson, G.B. Medullary thyroid carcinoma. Endocr. Pract. 2013, 19, 703–711. [Google Scholar] [CrossRef]
  39. Machens, A.; Dralle, H. Surgical Treatment of Medullary Thyroid Cancer. Recent Results Cancer Res. 2015, 204, 187–205. [Google Scholar] [CrossRef] [PubMed]
  40. Wells, S.A., Jr.; Asa, S.L.; Dralle, H.; Elisei, R.; Evans, D.B.; Gagel, R.F.; Lee, N.; Machens, A.; Moley, J.F.; Pacini, F.; et al. Revised American Thyroid Association guidelines for the management of medullary thyroid carcinoma. Thyroid 2015, 25, 567–610. [Google Scholar] [CrossRef] [PubMed]
  41. Tuttle, R.M.; Alzahrani, A.S. Risk Stratification in Differentiated Thyroid Cancer: From Detection to Final Follow-up. J. Clin. Endocrinol. Metab. 2019, 104, 4087–4100. [Google Scholar] [CrossRef] [PubMed]
  42. Bojoga, A.; Koot, A.; Bonenkamp, J.; de Wilt, J.; IntHout, J.; Stalmeier, P.; Hermens, R.; Smit, J.; Ottevanger, P.; Netea-Maier, R. The Impact of the Extent of Surgery on the Long-Term Outcomes of Patients with Low-Risk Differentiated Non-Medullary Thyroid Cancer: A Systematic Meta-Analysis. J. Clin. Med. 2020, 9, 2316. [Google Scholar] [CrossRef] [PubMed]
Diagnostics 13 00285 g001a 550Diagnostics 13 00285 g001b 550
Figure 1. Collision tumor. (A) low power view to show a TCT comprising MTC (upper left) and micro-PTC (lower right) components in the same thyroid lobe separated by non-tumoral thyroid tissue (HE, ×25); (B) higher magnification of the MTC component showing a classical MTC with amyloid deposits (HE, ×100); (C) higher magnification of a conventional PTC component (HE, ×200).
Figure 1. Collision tumor. (A) low power view to show a TCT comprising MTC (upper left) and micro-PTC (lower right) components in the same thyroid lobe separated by non-tumoral thyroid tissue (HE, ×25); (B) higher magnification of the MTC component showing a classical MTC with amyloid deposits (HE, ×100); (C) higher magnification of a conventional PTC component (HE, ×200).
Diagnostics 13 00285 g001aDiagnostics 13 00285 g001b
Diagnostics 13 00285 g002 550
Figure 2. Pathological features of TCTs’ MTC components. (A) classical solid MTC growth pattern (HE, ×200); (B) stromal amyloid present in the MTC component (HE, ×200); (C) lymphovascular invasion due to the MTC component (HE, ×200); (D) lymph node metastasis due to the MTC component (HE, ×100); strong and diffuse positivity of the MTC component for (E) calcitonin (IHC, anti-calcitonin antibody, ×100) and (F) chromogranin (IHC, anti-chromogranin antibody, ×100).
Figure 2. Pathological features of TCTs’ MTC components. (A) classical solid MTC growth pattern (HE, ×200); (B) stromal amyloid present in the MTC component (HE, ×200); (C) lymphovascular invasion due to the MTC component (HE, ×200); (D) lymph node metastasis due to the MTC component (HE, ×100); strong and diffuse positivity of the MTC component for (E) calcitonin (IHC, anti-calcitonin antibody, ×100) and (F) chromogranin (IHC, anti-chromogranin antibody, ×100).
Diagnostics 13 00285 g002
Diagnostics 13 00285 g003 550
Figure 3. Histo-morphological features of TCTs’ PTC components. (A) Follicular PTC growth pattern (HE, ×200); (B) conventional PTC growth pattern (HE, ×400); strong and diffuse positivity of PTC component for (C). CK19 (IHC, anti-CK19 antibody, ×100), (D) galectin-3 (IHC, anti-galectin-3 antibody, ×100), (E) HBME1 (IHC, anti-HBME1 antibody, ×100); (F) total negativity for CD56 (IHC, anti-CD56 antibody, ×100).
Figure 3. Histo-morphological features of TCTs’ PTC components. (A) Follicular PTC growth pattern (HE, ×200); (B) conventional PTC growth pattern (HE, ×400); strong and diffuse positivity of PTC component for (C). CK19 (IHC, anti-CK19 antibody, ×100), (D) galectin-3 (IHC, anti-galectin-3 antibody, ×100), (E) HBME1 (IHC, anti-HBME1 antibody, ×100); (F) total negativity for CD56 (IHC, anti-CD56 antibody, ×100).
Diagnostics 13 00285 g003
Table
Table 1. Clinical and histopathological aspects of the TCT cases.
Table 1. Clinical and histopathological aspects of the TCT cases.
Parameter Number of Cases
GenderM10 (28.57%)
F25 (71.42%)
Age at diagnosis<55 7 (20%)
≥55 28 (80%)
Location of the TCTs componentsRTL29 (82.85%)
LTL23 (65.71%)
Isthmus3 (8.57%)
Associated componentsMTC + PTC23 (65.71%)
FTC + PTC5 (14.28%)
HTC + PTC4 (11.42%)
ATC + PTC2 (5.71%)
PDTC + PTC1 (2.85%)
mETEMain component15 (42.85%)
Minor component2 (5.71%)
LVIMain component23 (65.71%)
Minor component2 (5.71%)
PNIMain component4 (11.42%)
Minor component0 (0%)
MultifocalityMain component5 (14.28%)
Minor component9 (25.71%)
LNMMain component9 (25.71%)
Minor component3 (8.57%)
Pathological N category
pNx14 (40%)
pN010 (28.57%)
pN1aMain component3 (8.57%)
Minor component2 (5.71%)
pN1bMain component6 (17.14%)
Minor component1 (2.85%)
Pathological T category
pT1Main component12 (34.28%)
Minor component35 (100%)
pT2Main component9 (25.71%)
Minor component0 (0%)
pT3Main component11 (31.42%)
Minor component0 (0%)
pT4Main component3 (8.57%)
Minor component0 (0%)
AJCC stage
IMain component19 (54.28%)
Minor component33 (94.28%)
IIMain component7 (20%)
Minor component2 (5.71%)
IIIMain component2 (5.71%)
Minor component0 (0%)
IVMain component7 (20%)
Minor component0 (0%)
Coexistent thyroid pathologies
Colloid goiter18 (51.42%)
Nodular goiter11 (31.42%)
Hashimoto thyroiditis6 (17.14%)
Abbreviations: M male, F female, LTL left thyroid lobe, RTL right thyroid lobe, mETE microscopic extrathyroidal extension, LVI lymphovascular invasion, PNI perineural invasion, LNM lymph node metastasis, PTC papillary thyroid carcinoma, MTC medullary thyroid carcinoma, FTC follicular thyroid carcinoma, HTC Hürthle cell thyroid carcinoma, PDTC poorly differentiated thyroid carcinoma, ATC anaplastic thyroid carcinoma
Table
Table 2. Pathological characteristics of the TCTs’ main components compared to their minor components (Chi-squared test).
Table 2. Pathological characteristics of the TCTs’ main components compared to their minor components (Chi-squared test).
Mean Valuep-Value
Diameter (mm)M35.4860.000
m3.946
Focality of the tumor (Unifocal/Multifocal)M1.8600.238
m1.740
mETE (Present/Absent)M1.4300.000
m1.060
LVI (Present/Absent)M1.6600.000
m1.060
PNI (Present/Absent)M1.1100.044
m1.000
Lymph node metastasis (Present/Absent)M1.4300.042
m1.140
Pathologic T category (T1/T2/T3/T4)M2.1400.000
m1.000
AJCC stage (I/II/III/IV)M1.9100.000
m1.060
p-value < 0.05 was considered to be statistically significant. Abbreviations: LTL left thyroid lobe, RTL right thyroid lobe, mETE microscopic extrathyroidal extension, LVI lymphovascular invasion, PNI perineural invasion, M main component, m minor component.
Table
Table 3. Pathological characteristics of the TCTs’ MTC components compared to PTC components (Chi-squared test).
Table 3. Pathological characteristics of the TCTs’ MTC components compared to PTC components (Chi-squared test).
Mean Valuep-Value
Diameter (mm)MTC27.4350.001
PTC6.174
Thyroid site (LTL/RTL/Isthmus)MTC2.5700.485
PTC2.430
Focality of the tumor (Unifocal/Multifocal)MTC1.8700.275
PTC1.740
mETE (Present/Absent)MTC1.3500.088
PTC1.130
LVI (Present/Absent)MTC1.4800.010
PTC1.130
PNI (Present/Absent)MTC1.1300.307
PTC1.040
Lymph node metastasis (Present/Absent)MTC1.4700.130
PTC1.200
pathologic T category (T1/T2/T3/T4)MTC1.7400.011
PTC1.130
AJCC stage (I/II/III/IV)MTC1.9600.004
PTC1.090
p-value < 0.05 was considered to be statistically significant. Abbreviations: LTL left thyroid lobe, RTL right thyroid lobe, mETE microscopic extrathyroidal extension, LVI lymphovascular invasion, PNI perineural invasion, MTC medullary thyroid carcinoma, PTC papillary thyroid carcinoma.
Table
Table 4. Pathological characteristics of the MTC-only tumors in relation to the histopathological prognostic features (Chi-squared test).
Table 4. Pathological characteristics of the MTC-only tumors in relation to the histopathological prognostic features (Chi-squared test).
Pathological CharacteristicsTumor Focalityp-ValueLVIp-Value
U (#20)M (#3) P (#8)A (#15)
Tumor size (mm)
<10 mm4 (20%)1 (33.3%)0.1240 (0%)5 (33.3%)0.032
10–40 mm11 (55%)0 (0%)3 (37.5%)8 (53.3%)
>40 mm5 (25%)2 (66.7%)5 (62.5%)2 (13.3%)
Growth pattern
Insular2 (10%)0 (0%)0.0241 (12.5%)1 (6.7%)1.000
Solid18 (90%)1 (33.3%)6 (75%)13 (86.7%)
Trabecular0 (0%)2 (66.7%)1 (12.5%)1 (6.7%)
AJCC stage
I12 (60%)1 (33.3%)0.1633 (37.5%)10 (66.7%)0.023
II4 (20%)0 (0%)1 (12.5%)3 (20%)
III2 (10%)0 (0%)0 (0%)2 (13.3%)
IV2 (10%)2 (66.7%)4 (50%)0 (0%)
p-value < 0.05 was considered to be statistically significant Abbreviations: LVI, lymphovascular invasion; P, present; A, absent; U, unifocal; M, multifocal; #, number of cases.
Table
Table 5. Pathological characteristics of the TCTs’ MTC components compared to MTC-only tumors.
Table 5. Pathological characteristics of the TCTs’ MTC components compared to MTC-only tumors.
Mean Valuet-Test ValueDegrees of Freedom (df)p-Value
Age at diagnosis (years)MTCc61.7001.11044.0000.273
MTC-only57.960
Sex (M/F)MTCc1.3000.66044.0000.513
MTC-only1.220
Diameter (mm)MTCc27.4300.56744.0000.574
MTC-only23.700
Thyroid site (LTL/RTL/Isthmus)MTCc1.5700.00044.0001.000
MTC-only1.570
Growth pattern (Solid/Trabecular/Insular/Lobular)MTCc2.740-0.73644.0000.466
MTC-only2.910
Amyloid (Present/Absent)MTCc1.5700.29044.0000.773
MTC-only1.520
Tumor focality (Unifocal/Multifocal)MTCc1.8700.00044.0001.000
MTC-only1.870
mETE (Present/Absent)MTCc1.3502.75529.8040.010
MTC-only1.040
LVI (Present/Absent)MTCc1.4800.88644.0000.380
MTC-only1.350
PNI (Present/Absent)MTCc1.1301.03636.2210.307
MTC-only1.040
Lymph node metastasis (Present/Absent)MTCc1.4700.50229.0000.619
MTC-only1.380
pathologic T category (T1/T2/T3/T4)MTCc1.7400.15244.0000.880
MTC-only1.700
AJCC stage (I/II/III/IV)MTCc1.9600.24244.0000.810
MTC-only1.870
p-value < 0.05 was considered to be statistically significant Abbreviations: M male, F female, LTL left thyroid lobe, RTL right thyroid lobe, mETE microscopic extrathyroidal extension, LVI lymphovascular invasion, PNI perineural invasion, MTCc medullary thyroid carcinoma component, MTC-only medullary thyroid carcinoma-only.
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.

Share and Cite

MDPI and ACS Style

Negura, I.; Ianole, V.; Danciu, M.; Preda, C.; Iosep, D.G.; Dănilă, R.; Grigorovici, A.; Ciobanu Apostol, D.G. Thyroid Collision Tumors: The Presence of the Medullary Thyroid Carcinoma Component Negatively Influences the Prognosis. Diagnostics 2023, 13, 285. https://doi.org/10.3390/diagnostics13020285

AMA Style

Negura I, Ianole V, Danciu M, Preda C, Iosep DG, Dănilă R, Grigorovici A, Ciobanu Apostol DG. Thyroid Collision Tumors: The Presence of the Medullary Thyroid Carcinoma Component Negatively Influences the Prognosis. Diagnostics. 2023; 13(2):285. https://doi.org/10.3390/diagnostics13020285

Chicago/Turabian Style

Negura, Ion, Victor Ianole, Mihai Danciu, Cristina Preda, Diana Gabriela Iosep, Radu Dănilă, Alexandru Grigorovici, and Delia Gabriela Ciobanu Apostol. 2023. "Thyroid Collision Tumors: The Presence of the Medullary Thyroid Carcinoma Component Negatively Influences the Prognosis" Diagnostics 13, no. 2: 285. https://doi.org/10.3390/diagnostics13020285

Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.

Article Metrics

Back to TopTop